Viewing nowNeo-Ban Tablets 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

MFDS item code 200807366 · Notified 2008.07.03 · Insurance code 653803180
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medication is used to reduce the risk of death in patients with essential hypertension, heart failure intolerant to ACE inhibitors (especially NYHA classification classes II-IV), and clinically stable patients with left ventricular dysfunction or impaired contractility following a myocardial infarction. It effectively controls hypertension, improves symptoms in heart failure patients, and contributes to increased survival rates after myocardial infarction. Therefore, this medication plays a very important role in the prevention and treatment of cardiovascular diseases.
(Tablets) * 40, 80, 160 mg 1. Essential hypertension Take with water during or between meals. If possible, it is recommended to take this medicine at the same time each day (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily and do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Over the following several weeks, increase the dose according to the patient's tolerability, giving 40 mg, 80 mg, and 160 mg per dose twice daily. Consider reducing the dose if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable not to exceed 80 mg daily. If administering 80 mg or more per day, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension: Children and adolescents under 18 years of age: Safety and efficacy have not been established. 6. Children: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; it should be discontinued immediately if pregnancy is confirmed. This medication must not be used in patients with allergies to its ingredients, severe liver or kidney dysfunction, or women who are pregnant or nursing. Particular caution is needed for the elderly or patients with high serum potassium levels, liver dysfunction, and other specific health conditions when using this medication. During treatment, symptoms such as dizziness or a sudden drop in blood pressure may occur, so monitoring should be conducted closely, especially when first taking the medication. Patients with heart failure or those who have had a myocardial infarction should have their kidney function monitored periodically while taking this medication, and any combination with other antihypertensive agents should be followed as per a physician’s instructions. This medication can dangerously increase blood potassium levels when taken with potassium-sparing diuretics or potassium supplements, so caution is advised. Taking this medication with non-steroidal anti-inflammatory drugs may decrease the antihypertensive effect and cause kidney function issues, so precautions are needed during concurrent use. This medication may cause dizziness during driving or operating machinery, so caution is required. In case of overdose, severe hypotension or decreased consciousness may occur, necessitating immediate contact with medical institutions for appropriate treatment. The safety and efficacy in children and adolescents have not been sufficiently established, so use in this age group is not recommended. When storing, keep it out of reach of children and do not transfer it to other containers for safety.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a tightly sealed container. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain its efficacy.
Pink round film-coated tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 80mg
Tablet · Prescription medication
Shinil Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.